Centiva Capital’s Haemonetics HAE Stock Holding History

Centiva Capital’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-2,500	Closed	-$163K	–	1640
2022 Q2	$163K	Buy	+2,500	New	+$148K	﹤0.01%	1333

Other funds holding HAE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $59.5B AUM 35.96% 1-Year Est. Return

Centiva Capital's HAE Position: Q3 2024 in Review

Centiva Capital sold out of Haemonetics (HAE) in Q3 2024, closing a stake of 4,557 shares — an estimated $377K sold.

Centiva Capital first reported a position in HAE in Q1 2021 and held it in 7 quarters. The position peaked at $1.26M in Q2 2021. 306 funds tracked by Wall St. Rank hold HAE as of Q3 2024.

Centiva Capital reported no remaining Haemonetics position as of Q3 2024 after selling out during the quarter.
Centiva Capital sold 4,557 Haemonetics shares in Q3 2024, an estimated $377K.
Centiva Capital first reported a position in Haemonetics in Q1 2021 and held it in 7 quarters.
Centiva Capital's Haemonetics position peaked at $1.26M in Q2 2021.
306 funds tracked by Wall St. Rank held Haemonetics as of Q3 2024.

Based on Centiva Capital's 13F filing for Q3 2024, filed 14 Nov 2024.